实时超声造影引导活检与传统超声引导活检在晚期慢性肝病背景下肝肿瘤诊断中的比较:一项前瞻性随机临床试验
该前瞻性随机临床试验于2011至2019年纳入144例晚期慢性肝病背景下肝肿瘤患者,随机分为超声造影引导活检组(CEUSLB,n=79)和传统超声引导活检组(USLB,n=65)。CEUSLB组诊断敏感度显著优于USLB组(94.74% vs 74.6%,p=0.001),且活检标本碎片长度和单次穿刺成功率均显著更高(p=0.022和p=0.0006),两组主要或次要并发症无差异(p=0.682)。作者结论认为CEUSLB是一项可行技术,可提高晚期慢性肝病背景下肝肿瘤的诊断敏感度。
要点
- 晚期慢性肝病背景下肝肿瘤活检,CEUSLB组敏感度94.74% vs USLB组74.6%(p=0.001)。
- CEUSLB组活检标本碎片长度和单次穿刺成功率均显著高于USLB组(p=0.022和p=0.0006)。
- 两组主要或次要并发症无差异(p=0.682)。
核心结论
- CEUSLB是一项可行技术,可提高晚期慢性肝病背景下肝肿瘤的诊断敏感度。
研究设计与样本
- 前瞻性随机临床试验,2011至2019年纳入144例晚期慢性肝病背景下肝肿瘤患者,随机分为CEUSLB组(n=79)和USLB组(n=65)。
诊断标准与关键数值
- CEUSLB组诊断敏感度94.74% vs USLB组74.6%(p=0.001)。
- CEUSLB组活检标本碎片长度和单次穿刺成功率均显著高于USLB组(p=0.022和p=0.0006)。
- 两组主要或次要并发症无差异(p=0.682)。
临床应用与阅片要点
- 作者结论认为CEUSLB是一项可行技术,可提高晚期慢性肝病背景下肝肿瘤的诊断敏感度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
We aimed to compare contrast-enhanced-guided liver biopsy (CEUSLB) and ultrasound-guided liver biopsy (USLB) in the diagnosis of focal liver lesions (FLLs) developed on a background of advanced chronic liver disease (ACLD). Between 2011 and 2019, patients diagnosed with liver tumors on a background of ACLD were evaluated for inclusion in the study. Patients were randomly assigned to the CEUSLB or USLB group. In total, 144 patients were randomly assigned to either CEUSLB (n = 79) or USLB (n = 65). Overall, in the CEUSLB group, the sensitivity was significantly better (94.74% vs. 74.6%, respectively; p = 0.001). Both the fragment length of the biopsy specimen and the single puncture success rate were statistically higher in the CEUSLB group (p = 0.022 and p = 0.0006, respectively). There was no difference in terms of major or minor complications (p = 0.682). CEUSLB is a feasible technique that increases the diagnostic sensitivity for liver tumors developed in ACLD.
引用
- Sparchez Z, Mocan T, Hagiu C, et al. Real-Time Contrast-Enhanced-Guided Biopsy Compared with Conventional Ultrasound-Guided Biopsy in the Diagnosis of Hepatic Tumors on a Background of Advanced Chronic Liver Disease: A Prospective, Randomized, Clinical Trial. Ultrasound Med Biol. 2019. PMID: 31447237. doi:10.1016/j.ultrasmedbio.2019.07.678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。